Jade Biosciences

JBIO Rare disease Lead: Phase 2 9 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-06

Catalyst timeline

JADE101 Ph2 startMid-2026JADE101 Ph2 start, Mid-2026, routine
Parade warrant corporate updateDec 31, 2026Parade warrant corporate update, Dec 31, 2026, routine
JADE201 Ph1 interim2027JADE201 Ph1 interim, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

JADE101

Protein Target: APRIL

IgA Nephropathy Phase 2 subcutaneous Paragon Therapeutics NCT07059312

JADE201

Protein Target: BAFF-R

Rheumatoid Arthritis Phase 1 subcutaneous Paragon Therapeutics NCT07533955
Undisclosed indication Preclinical Paragon Therapeutics

JADE301

Protein Target: IFN-β

Dermatomyositis Preclinical subcutaneous Paragon Therapeutics

Biotech Distilled coverage (9)

2026-08-11 UPDATE: Jade Biosciences (JBIO) - The Wildcard Has a Name: Interferon-Beta 🔒 Paid
2026-07-01 UPDATE: Jade Biosciences (JBIO) - The Wildcard Option Got Exercised 🔒 Paid
2026-06-04 UPDATE: Jade Biosciences (JBIO) - The Deal Priced at the Floor of My Range
2026-06-03 UPDATE: Jade Biosciences (JBIO) - The Dilution I Telegraphed, Just Not Through the Door I Expected
2026-06-02 UPDATE: Jade Biosciences (JBIO) - The Monkey Translated. The Stock Dropped 11.6% Anyway. 🔒 Paid
2026-05-29 UPDATE: Jade Biosciences (JBIO) - The Binary Has a Date: Monday, 8:00 a.m. ET 🔒 Paid
2026-05-27 UPDATE: Jade Biosciences (JBIO) - Two First-Patient-Dosed PRs Before the Monkey-to-Human Verdict 🔒 Paid
2026-05-08 UPDATE: Jade Biosciences (JBIO) - The $200M ATM Lands 6 Weeks Before the Monkey-to-Human Verdict 🔒 Paid
2026-05-06 Jade Biosciences (JBIO) - Scientific Deep Dive for JADE101 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.